联合检测血清IDH1和Cyfra21-1在非小细胞肺癌中的临床价值

The Clinical Value of Serum IDH1 and Cyfra21-1 in Non-small Cell Lung Cancer Patients

目的联合检测非小细胞肺癌(NSCLC)患者血清中异柠橡酸脱氢酶1(IDH1)和细胞角蛋白19片段(Cyfni21-1)的浓度水平,分析联合检测IDH1和Cyfra21-1在NSCLC中的临床应用价值。方法选取2016年5月至2018年8月首都医科大学附属北京胸科医院收治的NSCLC患者247例为NSCLC组(包括鳞癌67例、腺癌180例、I期+Ⅱ期69例、Ⅲ期+Ⅳ期178例),肺结核患者、肺炎患者或肺部良性结节患者80例为肺部良性疾病组,北京胸科医院体检正常的职工50例为健康组。采用酶联免疫法和流式荧光法检测3组患者血清中IDH1和Cyfra2M的浓度水平,分析这2种肿瘤标志物在NSCLC诊断中的临床意义。结果NSCLC组血清IDH1和Cyfra21-1水平高于肺部良性疾病组和健康组,差异有统计学意义(Z=6.414、6.811,P值均<0.001)。不同病理类型的NSCLC患者中,鱗癌的血清Cyfra21-1水平高于腺癌,差异有统计学意义(Z=2.114.P<0.05)。联合检测IDH1和Cyfra21-1在NSCLC患者中的敏感度为61.9%,高于单一肿瘤标志物。不同TNM分期的NSCLC患者中,Ⅰ期和Ⅱ期血清IDH1的敏感度(44.9%)高于Cyfra21-1(14.5%)结论联合检测血清IDH1和Cyfra21-1在NSCLC的辅助诊断和鉴别诊断中具有很好的临床应用价值。

Objective To detect the serum levels of isocitrate dehydrogenase 1(IDH1)and cytokerantin-19(Cyfra21-1)in non-small cell lung cancer(NSCLC)patients,and evaluate the clinical value of serum IDH1 combinded Cyfra21-1 in NSCLC patients.Methods The NSCLC group were 247 patients recruited from May 2016 to August 2018 in Beijing Chest Hospital affiliated to Capital Medical University(Including 67 cases of squamous cell carcinoma,180 cases of adenocarcinoma.69 cases of stage 1+11,178 cases of stage III+IV).The benign disease group were consisted of 80 patients,including pulmonary tuberculosis,pneumonia and benign nodule of the lung.The healthy group were 50 healthy staffs of Beijing Chest Hospital.The 3 groups levels of IDH 1 and Cyfra21-1 were detected by enzyme linked immunosorbent and flow fluorescence method,and analyzed the clinical value of the 2 tumor markers in diagnosing NSCLC.Results The levels of IDH 1 and Cyfra21-1 in NSCLC were higher than those of healthy group and benign disease group,the differences had statistical significance(Z=6.414,6.811,both P<0.001).In different pathology type of NSCLC patients,the level of Cyfra21-1 was higher in squamous cell carcinoma than that of adenocarcinoma,the differences had statistical significance(Z=2.114,P<0.05).The sensitivity of IDH1 combinded Cyfra2M in NSCLC was 61.9%,which was higher than that of single tumor marker.In different TNM stages of NSCLC patients,the sensitivity of IDH 1 was 44.9%in early NSCLC stages I and II.which was higher than that of Cyfra21-l(14.5%).Conclusions Combined detection of serum IDH1 and Cyfra21-1 has good clinical application value in auxiliary diagnosis and differential diagnosis of NSCLC.